Article
The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with…
ImmunoTargets and Therapy · 2024 · Tang X, Chen J, Peng W, Yang Z, Hu L, Ye Z, Fu Y, Hu D, Zhou Z, Chen M, Zhang Y, Wang JC
Key facts
| Title | The Efficacy and Safety of Bevacizumab Plus Anti-PD-1/PD-L1 Inhibitors in Combination with Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma |
|---|---|
| First author | Tang X, Chen J, Peng W, Yang Z, Hu L, Ye Z, Fu Y, Hu D, Zhou Z, Chen M, Zhang Y, Wang JC |
| Journal | ImmunoTargets and Therapy |
| Published | Oct 26, 2024 |
| DOI | 10.2147/ITT.S478685 |
| Product codes mentioned | CIT, CKA |
At a glance
- None FDA submissions mentioned
- 1–9 Product codes mentioned
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Literature
Peer-reviewed and preprint literature indexed by Orca1 and linked to the FDA submissions and product codes each article mentions. Only bibliographic details are shown here.
Source: Publisher and PubMed metadata; device mentions identified by Orca1